Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 12/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220943 | 0.91 | TRPM8 (0.51) | TRPM8NPC1L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL515901 | 0.89 | TRPM8 (0.54) | TRPM8NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL515902 | 0.89 | TRPM8 (0.54) | TRPM8NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL8171082 | 0.85 | CYP3A4 (0.46) | TRPM8ALDH1A1GLA | |
| SCHEMBL10220933 | 0.83 | TRPM8 (0.69) | TRPM8NPC1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL10579311 | 0.82 | NPC1 (0.54) | TRPM8NPC1L3MBTL1ALDH1A1GLA | |
| SCHEMBL10579307 | 0.82 | NPC1 (0.54) | TRPM8NPC1L3MBTL1ALDH1A1GLA | |
| SCHEMBL20314798 | 0.81 | GSTO1 (0.58) | TRPM8ALDH1A1GLA | |
| SCHEMBL8439016 | 0.80 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1HPGDGLA | |
| SCHEMBL5353769 | 0.77 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8071582-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110014271-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2011-01-20 | — | — | US | disclosed |
| US-7678785-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2010-03-16 | — | — | US | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029188-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | TRPM8 4470/4885NPC1 599/4885L3MBTL1 1325/4885 |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | DPM1, ERG28, IL4I1 | TRPM8 4349/4885NPC1 1324/4885L3MBTL1 2070/4885 |
| US-20110014271-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | TRPM8 4470/4885NPC1 599/4885L3MBTL1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.